Saturday, 17 October 2026European Markets

CROSSWOOD Stock Is 20% Up In The Last 5 Sessions

Loading stream...

(vianews) - shares of crosswood (cac 40: cros.pa) jumped by a staggering 20.55% in 5 sessions from €7.3 to €8.80 at 14:54 est on thursday, following the last session's upward trend. cac 40 is jumping 0.34% to €7,341.52, after two successive sessions in a row of losses.

crosswood's last close was €8.80, 6.02% above its 52-week high of €8.30.

about crosswood

crosswood sa engages in real estate activity in france. its property portfolio includes shops and offices, and housing properties. the company was formerly known as desquenne et giral. crosswood sa was incorporated in 1935 and is based in paris, france. crosswood sa operates as a subsidiary of compagnie financiere de broceliande.

earnings per share

as for profitability, crosswood has a trailing twelve months eps of €0.55.

pe ratio

crosswood has a trailing twelve months price to earnings ratio of 16. meaning, the purchaser of the share is investing €16 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.48%.

more news about crosswood (cros.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com